Possible Roles of Epidermal Opioid Systems in Pruritus of Atopic Dermatitis

Andoh, 2004, Intradermal nociceptin elicits itch-associated responses through leukotriene B(4) in mice, J Invest Dermatol, 123, 196, 10.1111/j.0022-202X.2004.22704.x Autelitano, 1989, Hormonal regulation of POMC gene expression, Annu Rev Physiol, 51, 715, 10.1146/annurev.ph.51.030189.003435 Ballantyne, 1988, Itching after epidural and spinal opiates, Pain, 33, 149, 10.1016/0304-3959(88)90085-1 Belcheva, 2005, Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes, J Biol Chem, 280, 27662, 10.1074/jbc.M502593200 Bergasa, 1992, A controlled trial of naloxone infusions for the pruritus of chronic cholestasis, Gastroenterology, 102, 544, 10.1016/0016-5085(92)90102-5 Bigliardi, 1998, Expression of μ-opiate receptor in human epidermis and keratinocytes, J Invest Dermatol, 111, 297, 10.1046/j.1523-1747.1998.00259.x Bigliardi, 2002, Specific stimulation of migration of human keratinocytes by mu-opiate receptor agonists, J Recept Signal Transduct Res, 22, 191, 10.1081/RRS-120014595 Bigliardi, 2007, Treatment of pruritus with topically applied opiate receptor antagonist, J Am Acad Dermatol, 56, 979, 10.1016/j.jaad.2007.01.007 Bigliardi-Qi, 2000, Beta-endorphin stimulates cytokeratin 16 expression and downregulates mu-opiate receptor expression in human epidermis, J Invest Dermatol, 114, 527, 10.1046/j.1523-1747.2000.00801.x Bigliardi-Qi, 2007, Deletion of mu- and kappa-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior, J Invest Dermatol, 127, 1479, 10.1038/sj.jid.5700661 Bigliardi-Qi, 2005, Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis, Dermatology, 210, 91, 10.1159/000082563 Bigliardi-Qi, 2004, Mu-opiate receptor and beta-endorphin expression in nerve endings and keratinocytes in human skin, Dermatology, 209, 183, 10.1159/000079887 Bodnar, 2006, Endogenous opiates and behavior: 2005, Peptides, 27, 3391, 10.1016/j.peptides.2006.07.011 Bohn, 2000, Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated extracellular signal-regulated kinase phosphorylation is dynamin-dependent in C6 glioma cells, J Neurochem, 74, 574, 10.1046/j.1471-4159.2000.740574.x Borner, 2002, Involvement of activator protein-1 in transcriptional regulation of the human mu-opioid receptor gene, Mol Pharmacol, 61, 800, 10.1124/mol.61.4.800 Boukamp, 1988, Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line, J Cell Biol, 106, 761, 10.1083/jcb.106.3.761 Civelli, 1985, Sequence and expression of the rat prodynorphin gene, Proc Natl Acad Sci USA, 82, 4291, 10.1073/pnas.82.12.4291 Cousins, 1984, Intrathecal and epidural administration of opioids, Anesthesiology, 61, 276, 10.1097/00000542-198409000-00008 Day, 1998, Prodynorphin processing by proprotein convertase 2. Cleavage at single basic residues and enhanced processing in the presence of carboxypeptidase activity, J Biol Chem, 273, 829, 10.1074/jbc.273.2.829 Gasparro, 1997, Psoralen photobiology: the relationship between DNA damage, chromatin structure, transcription, and immunogenic effects, Recent Results Cancer Res, 143, 101, 10.1007/978-3-642-60393-8_8 Gilmore, 1989, The opioid specificity of beta-endorphin enhancement of murine lymphocyte proliferation, Immunopharmacology, 17, 19, 10.1016/0162-3109(89)90004-0 Goldstein, 1989, Multiple opioid receptors: ligand selectivity profiles and binding site signatures, Mol Pharmacol, 36, 265 Greaves, 2005, Itch in systemic disease: therapeutic options, Dermatol Ther, 18, 323, 10.1111/j.1529-8019.2005.00036.x Henseler, 1981, Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres, Lancet, 1, 853, 10.1016/S0140-6736(81)92137-1 Inan, 2004, Kappa opioid agonists suppress chloroquine-induced scratching in mice, Eur J Pharmacol, 502, 233, 10.1016/j.ejphar.2004.09.010 Kauser, 2003, Regulation of human epidermal melanocyte biology by beta-endorphin, J Invest Dermatol, 120, 1073, 10.1046/j.1523-1747.2003.12242.x Kim, 2004, Neuron-restrictive silencer factor (NRSF) functions as a repressor in neuronal cells to regulate the mu opioid receptor gene, J Biol Chem, 279, 46464, 10.1074/jbc.M403633200 Kim, 2005, Poly(C) binding protein family is a transcription factor in mu-opioid receptor gene expression, Mol Pharmacol, 68, 729, 10.1124/mol.105.012245 Kinouchi, 1991, Evidence for kappa 1 opioid receptor multiplicity in the guinea pig cerebellum, Eur J Pharmacol, 207, 135, 10.1016/0922-4106(91)90088-Y Konkoy, 1993, Relationship between kappa 1 opioid receptor binding and inhibition of adenylyl cyclase in guinea pig brain membranes, Biochem Pharmacol, 4, 207, 10.1016/0006-2952(93)90394-C Martey, 2005, Inhibition of interferon-gamma signaling by a mercurio-substituted dihydropsoralen in murine keratinocytes, Biochem Pharmacol, 70, 1726, 10.1016/j.bcp.2005.10.001 Metze, 1999, Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases, J Am Acad Dermatol, 41, 533 Nagase, 1998, Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan, Chem Pharm Bull (Tokyo), 46, 366, 10.1248/cpb.46.366 Nock, 1990, Affinity of drugs and peptides for U-69,593-sensitive and -insensitive kappa opiate binding sites: the U-69,593-insensitive site appears to be the beta endorphin-specific epsilon receptor, J Pharmacol Exp Ther, 254, 412 Park, 2005, Retinoic acid-induced chromatin remodeling of mouse kappa opioid receptor gene, J Neurosci, 25, 3350, 10.1523/JNEUROSCI.0186-05.2005 Peer, 1996, Randomised crossover trial of naltrexone in uraemic pruritus, Lancet, 348, 1552, 10.1016/S0140-6736(96)04176-1 Rau, 2005, Diverse immunocytochemical expression of opioid receptors in electrophysiologically defined cells of rat dorsal root ganglia, J Chem Neuroanat, 29, 255, 10.1016/j.jchemneu.2005.02.002 Ree, 1981, Ultrastructural studies on the effect of photoactivated 8-methoxy psoralen. Nuclear changes in a human epithelial cell line, Acta Pathol Microbiol Scand [A], 89, 81 Salemi, 2005, Detection of kappa and delta opioid receptors in skin-outside the nervous system, Biochem Biophys Res Commun, 338, 1012, 10.1016/j.bbrc.2005.10.072 Satoh, 1995, Molecular pharmacology of the opioid receptors, Pharmacol Ther, 68, 343, 10.1016/0163-7258(95)02011-X Slominski, 2000, Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress, Physiol Rev, 80, 979, 10.1152/physrev.2000.80.3.979 Smith, 1988, Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues, Endocrine Rev, 9, 159, 10.1210/edrv-9-1-159 Stander, 2002, Localization of mu-opioid receptor 1A on sensory nerve fibers in human skin, Regul Pept, 110, 75, 10.1016/S0167-0115(02)00159-3 Stefano, 2000, Endogenous morphine, Trends Neurosci, 23, 436, 10.1016/S0166-2236(00)01611-8 Togashi, 2002, Antipruritic activity of the kappa-opioid receptor agonist, TRK-820, Eur J Pharmacol, 435, 259, 10.1016/S0014-2999(01)01588-6 Tseng, 1995, 524 Umeuchi, 2003, Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system, Eur J Pharmacol, 477, 29, 10.1016/j.ejphar.2003.08.007 Wakasa, 2004, Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys, Life Sci, 75, 2947, 10.1016/j.lfs.2004.05.033 Zadina, 1999, Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density, Ann NY Acad Sci, 897, 136, 10.1111/j.1749-6632.1999.tb07885.x